TerminatedNot Applicable

Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

Stopped: investigateur decision

France8 participantsStarted 2018-07-01

Plain-language summary

Kidney transplantation is the best renal-replacement in the setting of end-stage renal disease. However, some transplant candidates have developed anti-HLA alloantibodies (human leukocyte antigen). When they are numerous and when their strength assessed by mean fluorescence intensity (MFI) is high it is very complicated to find-out a suitable kidney allograft against which the recipient has a negative cross-match. In such a case the only hope for the patient is desensitization therapy, whereby the treatment will decrease anti-HLA alloantibodies below a threshold, i.e. MFI \< 3,000, enabling kidney transplantation without risking antibody-mediated rejection. Desensitization relies on i) apheresis technics in order to withdraw circulating anti-HLA antibodies, and ii) immunosuppression, i.e. rituximab or tocilizumab, targeting B-lymphocytes, and tacrolimus/mycophenolic acid/steroids targeting T-cells. The type of apheresis is guided by the pre-desensitization MFI of anti-HLA alloantibodies, e.g. double filtration plasmapheresis or semispecific immunoadsorption. Likely the choice between rituximab and tocilizumab depends also on predesensitization anti-HLA antibody MFIs. At the end of the desensitization process, the patient will be able to get a kidney transplant either from a live-donor or from a deceased donor.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients on the kidney transplant list, waiting for a first or repeat transplant * Presence of anti HLA antibodies either class I and/or II * Sensitized against a potential living donor or have been on the waiting list for at least 3 years and having no potential live-donor * Patients eligible for desensitization will receive either rituximab alone, or rituximab plus apheresis, or tocilizumab before rituximab * Normal recent (\<6 months) cardiac workup * Vaccinated against pneumococcus and meningococcus B and C * Willingness of the patient to undergo the desensitization process and Express consent of the patient * for women of childbearing age, effective contraception or abstinence * Affiliated to a social security scheme or of such a scheme Exclusion Criteria: * Active underlying infections or neoplasia * Pregnant women, parturient or breastfeeding * Subject in exclusion period of another study * Subject under administrative or judicial control * Subject who cannot be contacted in an emergency * Rituximab contra indication: hypersensitivity (to active substance or murine protein), active and severe infections, patients in a severely immunocompromised state, severe heart failure or severe, uncontrolled cardiac disease. * Tocilizumab contra indication: hypersensitivity, active and severe infections. Apheresis contra indication: active and severe infection, untreated or instable coagulation disorders, unstable coronary disease, recent stroke, hemodynami…

What they're measuring

Description of the results of the strategy of desensitization in patients who will access to kidney transplantation from deceased or living donors.

Timeframe: at day 1 start of desensitization, at day 0 of Graft

Trial details

NCT IDNCT03507348

SponsorUniversity Hospital, Grenoble

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-11-21